Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Does Initial Atopic Dermatitis Severity Affect Long-Term Abrocitinib Outcomes? A Post Hoc Analysis of Two Randomized Trials

  • By

  • Andrew E. Pink

  • Zakiya P. Rice

  • Melinda J. Gooderham

  • Fang Wang

  • Andreas Wollenberg

  • Pinaki Biswas

  • Gary Chan

  • Justine Alderfer

  • Melissa Watkins

  • October 8, 2026

Share

Original Source(s)

Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials

  • by Andrew E. Pink, Zakiya P. Rice, Melinda J. Gooderham, Fang Wang, Andreas Wollenberg, Pinaki Biswas, Gary Chan, Justine Alderfer, Melissa Watkins

  • October 8, 2026

Related Content

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

Product Labels Miss Hidden Chemicals

Testing found that nearly 60% of top-rated "Go" products failed contamination testing.

FDA approves first therapy for symptomatic dermographism

The oral BTK inhibitor produced a complete hive response in 29.3% of treated patients at week 12.